Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).

Yuankai Shi,Lin Wu,Xinmin Yu,Puyuan Xing,Yan Wang,Jianying Zhou,Airong Wang,Jianhua Shi,Yi Hu,Ziping Wang,Guangyu An,Yong Fang,Sanyuan Sun,Caicun Zhou,Changli Wang,Feng Ye,Xingya Li,Junye Wang,Mengzhao Wang,Yunpeng Liu,Yanqiu Zhao,Ying Yuan,Jifeng Feng,Zhendong Chen,Jindong Shi,Tao Sun,Gang Wu,Yongqian Shu,Qisen Guo,Yi Zhang,Yong Song,Shucai Zhang,Yuan Chen,Wei Li,Hongrui Niu,Wenwei Hu,Lijun Wang,Jianan Huang,Yang Zhang,Ying Cheng,Zhengdong Wu, Bo Peng,Jiya Sun,Christoph Mancao,Yanqi Wang,Luyao Sun

Cancer communications (London, England)（2022）

Cited 7|Views60
No score
Abstract
Compared with docetaxel, sintilimab significantly improved the OS, PFS, and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC.
More
Translated text
Key words
Carcinoma, squamous cell,Immunotherapy,Non-small cell lung cancer,Randomized controlled trial,Sintilimab,Survival
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined